RxDoctor Payments Data

Felicia Cooper

Family · Paducah, KYNPI 1508314212

Payments from drug & device makers

$4,044in general payments, 2019–2025

Across 266 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$519
  • Pfizer$351
  • Sanofi-aventis U.S. LLC$310
  • Boehringer Ingelheim$277
  • AstraZeneca$190
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,044 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,983
Medicare patients
201
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide279$278,990
EliquisApixaban80$63,898
JardianceEmpagliflozin60$57,649
FarxigaDapagliflozin Propanediol47$40,975
Invega SustennaPaliperidone Palmitate12$40,900
TrulicityDulaglutide27$24,687
Tresiba Flextouch U-200Insulin Degludec15$21,517
JanuviaSitagliptin Phosphate18$18,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,088
MounjaroTirzepatide14$14,839
QuliptaAtogepant12$13,558
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$13,481
TradjentaLinagliptin16$12,899
MyrbetriqMirabegron18$12,653
Bydureon BciseExenatide Microspheres16$12,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$519$278,990279 claims
Boehringer IngelheimJardiance, Tradjenta$277$70,54876 claims
PfizerEliquis$351$63,89880 claims
AstraZenecaFarxiga, Breztri Aerosphere$190$51,00563 claims
Lilly USA, LLCTrulicity, Mounjaro$98$39,52641 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$42$31,07360 claims
AbbVieQulipta, Linzess, Creon$1,388$27,14835 claims
MerckJanuvia$96$18,90218 claims
Astellas Pharma US IncMyrbetriq$35$12,65318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →